Chronic hepatitis B virus (HBV) infection remains a leading cause of hepatic inflammation
and damage. The pathogenesis of chronic hepatitis B (CHB) infection is predominantly …

Objective To explore dynamic changes of cytokines and virological markers associated with
hepatitis B surface antigen (HBsAg) loss during peginterferon alpha-2a (PEG-IFN α-2a) …

Objective The aims of this study were to investigate the kinetic changes of serum, virological,
and immunological markers during entecavir (ETV) antiviral therapy and to explore whether …

Objective The aim of this study was to explore the profile of cytokine changes during the
combination therapy with pegylated interferon alpha (PEG-IFN-α) and its relationship with …

Hepatitis B surface antigen (HBsAg) clearance is considered as functional cure in patients
with chronic hepatitis B (CHB). This study aimed to assess the durability of HBsAg clearance …

Background To investigate the effect of intermittent interferon therapy mode on the
disappearance of hepatitis B surface antigen (HBsAg) in chronic hepatitis B (CHB) patients …

Background and objectives Pegylated interferon alpha-2a (peg-IFN α-2a) and entecavir
(ETV) are both recommended as the first-line antiviral drugs for chronic hepatitis B (CHB) at …

BACKGROUND: Various biological markers have been proposed to predict subclinical
events in subjects with chronic hepatitis B virus (HBV). However, studies regarding chronic …

Background The relationship between the serum transforming growth factor (TGF)-β level
and HBsAg loss has not been clearly elaborated in patients with chronic hepatitis B (CHB) …

Objective This study aimed to investigate whether cytokine profiles and virological markers
might add value in monitoring the effects of peginterferon (PEG-IFN) therapy for hepatitis B e …